Patents by Inventor Jonathan H. Lebowitz
Jonathan H. Lebowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9469683Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: GrantFiled: November 7, 2014Date of Patent: October 18, 2016Assignee: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20150064157Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: November 7, 2014Publication date: March 5, 2015Inventors: Jonathan H. LeBowitz, John Maga
-
Publication number: 20120295327Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: May 25, 2012Publication date: November 22, 2012Applicant: Biomarin Pharmaceutical Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20120213762Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan H. LeBowitz, John Maga
-
Patent number: 8207114Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: November 2, 2009Date of Patent: June 26, 2012Assignee: Biomarin Pharmaceutical Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20120141452Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: August 3, 2011Publication date: June 7, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20110223147Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.Type: ApplicationFiled: May 7, 2009Publication date: September 15, 2011Applicant: ZYSTOR THERAPEUTICS, INC.Inventors: Jonathan H. Lebowitz, John Maga
-
Patent number: 7858576Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: May 30, 2007Date of Patent: December 28, 2010Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20100075906Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: November 2, 2009Publication date: March 25, 2010Applicant: Zystor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Patent number: 7629309Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: November 3, 2004Date of Patent: December 8, 2009Assignee: Zystor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20090203575Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: February 19, 2009Publication date: August 13, 2009Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 7560424Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: October 16, 2002Date of Patent: July 14, 2009Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20090029467Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: May 30, 2007Publication date: January 29, 2009Applicant: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 7396811Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: GrantFiled: April 30, 2002Date of Patent: July 8, 2008Assignee: ZyStor Therapeutics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20040214757Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: October 28, 2004Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Publication number: 20040005309Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: October 16, 2002Publication date: January 8, 2004Applicant: Symbiontics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley, William S. Sly
-
Publication number: 20040006008Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: October 16, 2002Publication date: January 8, 2004Applicant: Symbiontics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Publication number: 20030082176Abstract: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.Type: ApplicationFiled: April 30, 2002Publication date: May 1, 2003Applicant: Symbiontics, Inc.Inventors: Jonathan H. LeBowitz, Stephen M. Beverley
-
Patent number: 6410516Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: June 25, 2002Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical ResearchInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6150090Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: November 21, 2000Assignees: Massachusetts Institute of Technology, Whitehead Institute, President and Fellows of Harvard CollegeInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
